LYMPHIR Breakthrough: Citius Oncology Strengthens Governance, Insider Buy‑Backs, and Fast‑Track CTCL Therapy
Discover how Citius Oncology’s new director, insider buying and LYMPHIR’s Phase‑3 success could reshape CTCL treatment and investor confidence.
4 minutes to read